Drug Profile
VAL 201
Alternative Names: BC-201; VAL-201; VAL-301Latest Information Update: 06 Aug 2023
Price :
$50
*
At a glance
- Originator Cancer Research Technology
- Developer ValiRx
- Class Antineoplastics; Peptides
- Mechanism of Action DNA synthesis inhibitors; Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer; Solid tumours
- Preclinical Endometriosis
- Research Inflammation
Most Recent Events
- 06 Aug 2023 ValiRx has a patent pending for VAL 301 in European Union, Russia and US (ValiRx website, August 2023)
- 04 Aug 2023 ValiRx files a PCT patent family applications for VAL 201 in worldwide (ValiRx website, August 2023)
- 04 Aug 2023 ValiRx files a PCT patent family applications for VAL 301 in worldwide (ValiRx website, August 2023)